Post by Biogen on X
Biogen@biogen
X#News: Today, the FDA approved a new dosing regimen option for our spinal muscular atrophy (SMA) therapy. This approval represents an important step toward expanding options for people living with SMA. Learn more: t.co
9 likes0 repliesPosted Mar 30, 2026